Statin treatment may reduce cardiovascular risk in people with HIV not only by lowering cholesterol but also by reducing coronary plaque and inflammation, Professor Steven Grinspoon told the Conference on Retroviruses and Opportunistic Infections (CROI 2025) in San Francisco last week.
He was reporting results from a substudy of the REPRIEVE trial, the international study which showed that daily use of pitavastatin by people with HIV reduced the risk of a major cardiovascular event such as stroke or heart attack by 36% in people judged to have a low-to-moderate risk of heart disease.
The substudy looked at how underlying coronary artery disease and inflammation affected the risk of cardiovascular disease and the response to statin treatment in 804 participants from the United States. It found some evidence that trial participants with pre-existing coronary plaque derived greater benefit from taking pitavastatin as preventive treatment than those without signs of coronary artery disease.
Read the full news story at aidsmap.
View all aidsmap reports from CROI 2025
Source : aidsmap
Related HIV and Co-Infections News
-
New treatment for cryptococcal meningitis enters Phase II trial as global HIV funding cuts threaten to cause a massive increase in advanced HIV disease
-
Molecular stool test could improve detection of TB in adults with HIV
-
Montreal researchers explore different factors affecting brain health and frailty among older people with HIV
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.